“Safety and Efficacy of Apremilast Through 104 Weeks in Patients Swith Moderate-to-Severe Psoriasis Who Continued on Apremilast or Switched from Etanercept Treatment in the LIBERATE Study”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s32, https://doi.org/10.25251/skin.1.supp.31.